Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Oral Hypoglycemic

Therapeutic area intelligence for Oral Hypoglycemic with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Companies
1

Companies

Indicus Pharma →

Assets

Chartwell →
Indicus →

Recent signals(2)

StrategyJune 27, 2026

FDA Grants AP Status for Metformin Hydrochloride ANDA075972

The FDA has granted an Abbreviated Approval (AP) status for ANDA075972, a generic formulation of Metformin Hydrochloride submitted by Chartwell.

StrategyJune 26, 2026

Indicus Pharma's Metformin Hydrochloride ANDA079148 Receives AP Status

Indicus Pharma's ANDA for Metformin Hydrochloride has been granted Abbreviated Approval (AP) status by the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.